Skip To The Main Content

Browse these ideas available for licensing that have the potential to improve lives while creating jobs to support and grow the region.

All technologies
 are listed as non-confidential technical summaries.

Technologies were generated by academic institutions, entrepreneurs, and corporations.

Click the Tech Search button below to have Whiteboard 2 Boardroom® staff complete a personalized search for innovations to license from our research institution partners.

The most recent innovations from our partners are featured separately and organized by category. All listings are updated as new technology opportunities become available. 

For assistance in connecting with, or attaining further information on any of these technologies, please contact us.

Diagnostic Test for Severe Early-Onset Preeclampsia

Researchers at the University of Missouri (MU) have developed a novel diagnostic test that can be used for the early detection of preeclampsia. This test identifies an early biomarker that will enable obstetricians to diagnose and treat the condition before symptoms emerge. Background Severe early-onset preeclampsia (sPE) is a pathological condition that develops in women during pregnancy and often results in serious or fatal complications for both the mother and her unborn child. Preeclampsia is one of the potential causes of maternal and fetal morbidity and mortality that affects 7-10% of pregnancies. Preeclampsia is a multi-organ and heterogenous disorder that if left untreated could lead to eclampsia, which is a life threatening maternal neurovascular disorder. Currently there are no diagnostics for preeclampsia preceding the onset of symptoms, which include hypertension, increased proteinuria and extreme edema. As such, pregnant women are often unaware of the development of sPE until serious symptoms present. The novel diagnostic test in development at MU presents a new, presymptomatic, early-stage diagnostic with the potential to change the impact of preeclampsia on pregnant women and their children.

 Early diagnosis of preeclampsi

 Earliest diagnostic available
 Inexpensive
 Non-invasive Patent Status

Patent pending

State of Development

Additional Details


University of Missouri-Columbia

Intellectual Property Protection

Pending Patent

Interested? Request More Information